Bristol gains approval of first-in-class immunotherapy for melanoma Opdualag

Mar. 19, 2022 1:10 PM ETBristol-Myers Squibb Company (BMY)By: Jonathan Block, SA News Editor15 Comments

Stock Markets Open One Day After Steep Drop Over Apple"s Revised Forecast

Drew Angerer/Getty Images News

  • The U.S. FDA has approved Bristol-Myers Squibb's (NYSE:BMY) Opdualag, a combination of Opdivo (nivolumab) and the novel agent relatlimab, for unresectable or metastatic melanoma.
  • Opdivo is a PD-1 inhibitor with many cancer indications while relatlimab is a novel LAG-3 blocker.
  • In the phase 2/3 RELATIVITY-047 trial, Opdualag more than doubled median progression-free survival compared to Opdivo alone -- 10.1 months vs. 4.6 months.
  • The approval is for adults and children 12 and older.
  • Bristol (BMY) has previously stated Opdualag could reach annual sales of $4B by 2029.
  • Check out why Seeking Alpha contributor Edmund Ingham says that Bristol (BMY) is a buy.

Recommended For You

Comments (15)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.